Sharemaestro company-news research for Novo Nordisk A/S (NVO), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NYSE
United States
Measured evidence
Company news sentiment
NVO news sentiment
Novo Nordisk A/S
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score51Neutral is 50
Balanced news tone
45/100 evidence confidence
93% direct company focus
31 current stories across 13 publishers
Current company news
Balanced news tone
The score uses 31 current company stories from 13 publishers.
Observed headline tone52/100
→
Published 30-day score51/100
Latest source headline
Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race
finance.yahoo.com · 13 Aug 2026 18:38
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
31 current stories are mapped specifically to NVO.
The score uses 13 publishers rather than depending on one outlet.
The current stories agree at 82/100.
What limits the score
No major limit stands out.
51/100
News scoreBalanced news tone
45/100
Confidencebuilding confidence
93%/100
Company news31 company stories
82/100
Story agreement18/100 difference
News history
Daily score and story count over 30 days
16 Jul31 Jul14 Aug
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence25
1.233 after freshness weightingSource breadth100
13 independent publishersCompany relevance93
share tied directly to this companyFreshness77
recency-weighted evidenceAgreement82
how closely stories agreePublisher mix21
less reliance on one publisherPrice and news history
News score and weekly price over 26 weeks
News tone and price action are not far from neutral.
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
07 Aug 202647USD 47.26+0.4%
31 Jul 202649USD 47.08-3.5%
24 Jul 202651USD 48.77-3.1%
17 Jul 202651USD 50.32+1.7%
10 Jul 202651USD 49.48-1.9%
03 Jul 202651USD 50.43+4.9%
26 Jun 202650USD 48.07+11.3%
Value support
News subjects
What is shaping the score
Market update5017 stories · 55%
Earnings617 stories · 23%
Regulatory and legal323 stories · 10%
Capital return652 stories · 6%
Analyst action442 stories · 6%
Source mix
Where the evidence comes from
finance.yahoo.com5211 stories · 35%
Seeking Alpha353 stories · 10%
foreignpolicyjournal.com633 stories · 10%
MT Newswires462 stories · 6%
simplywall.st502 stories · 6%
Market source502 stories · 6%
The Globe and Mail651 stories · 3%
Recurring subjects
Subjects appearing most often
Pharma5Earnings5EARNINGS4Healthcare3Diabetes3PHARMA2Obesity2Lawsuit2Fourth Quarter2DIABETES2
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
20 Jun50 neutral14 Aug 00:16
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 14 Aug 00:16 | 54 | +0 | 57/100 (-1) | 60 (0) | Measured |
| 13 Aug 23:59 | 54 | +4 | 58/100 (+7) | 60 (+9) | Measured |
| 12 Aug 23:59 | 50 | +1 | 51/100 (0) | 51 (+4) | Measured |
| 11 Aug 23:59 | 49 | -1 | 51/100 (+1) | 47 (+5) | Measured |
| 10 Aug 23:59 | 50 | +2 | 50/100 (+11) | 42 (+12) | Measured |
| 09 Aug 23:59 | 48 | +0 | 39/100 (-1) | 30 (0) | Measured |
| 08 Aug 23:59 | 48 | +1 | 40/100 (+3) | 30 (+4) | Measured |
| 07 Aug 23:59 | 47 | -3 | 37/100 (+10) | 26 (+2) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#150Tone
finance.yahoo.comDirect company coverageStored article
Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market's thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly (NYSE:LLY) like a winner-takes-all fight. The obesity market could top $100 billion annually by 2030, and different patients will want different drugs, delivery methods and trade-offs. For Novo, that is more than a talking point. It is the heart of the comeback story after Lilly's Zepbound grabbed moment
Clinical TrialsObesityPharmaValuation
- Published
- 13 Aug 2026 18:38
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 3.9% · 0.1d old
- Duplicates
- 3 consolidated
#235Tone
finance.yahoo.comDirect company coverageStored article
Novo Nordisk Escalates Weight-Loss War With Eli Lilly
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) CEO Mike Doustdar is defending the drugmaker's lawsuit against Eli Lilly (NYSE:LLY), escalating a fight over how the two companies market their blockbuster obesity treatments. The legal battle matters because Lilly has seized the lead in the U.S. obesity-drug market, raising the stakes for Novo as it tries to narrow the efficacy gap consumers may perceive between Wegovy and Zepbound. Is LLY fairly valued? Test your thesis with our free DCF calculator. Novo Nordisk develops treatments for diabetes, obesity and other chronic disea
AdvertisingLawsuitMarket ShareObesity TreatmentsPharma
- Published
- 13 Aug 2026 17:32
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 13.9% · 0.1d old
- Duplicates
- 15 consolidated
#376Tone
finance.yahoo.comDirect company coverageStored article
Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?
Novo Nordisk (NYSE: NVO) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the company's most recent financial update, for the second quarter, erased much of those gains. In both cases, the market's reaction was largely driven by the performance of the Wegovy pill, the first oral GLP-1 approved for weight loss, which Novo Nordisk launched in the U.S. in January. The Wegovy pill beat expectations in the first quarter but came up short in the second. What does this mean for the company's prospects?Image source: The Motley
EarningsEarnings GrowthHealthcarePharmaWeight Loss
- Published
- 13 Aug 2026 17:20
- News subject
- Earnings
- Why this score
- Beat expectations
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 13.3% · 0.1d old
- Duplicates
- 15 consolidated
#431Tone
finance.yahoo.comDirect company coverageStored article
Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the country. The approval adds a non injectable option alongside Novo Nordisk's GLP 1 based obesity drugs and could affect demand patterns if Foundayo is adopted in public healthcare settings. In the US, Amazon Pharmacy launches a new Medicare weight loss drug program priced at $50 per month that will include Novo Nordisk an
Balance SheetHealthcareObesity CarePharmaceuticalsPricing PressureRevenue Growth
- Published
- 13 Aug 2026 15:12
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 12.2% · 0.2d old
- Duplicates
- 63 consolidated
#566Tone
finance.yahoo.comDirect company coverageStored article
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?
Novo Nordisk NVO remains a dominant player in the GLP-1 market, marketing its semaglutide drugs Ozempic and Rybelsus for type II diabetes (T2D) and Wegovy for chronic weight management. However, the company's core franchise is facing mounting competitive pressure from Eli Lilly LLY, despite NVO delivering a better-than-expected second-quarter 2026 performance. NVO's reported second-quarter sales rose 3% to $12.21 billion (DKK 78.5 billion) at constant exchange rates (CER). More importantly, its key GLP-1 brands showed signs of slowing. Ozempic generated $4.88 billion (DKK 31.4 billion) in repo
CompetitionDiabetesFourth QuarterGlp 1ObesityPharma
- Published
- 13 Aug 2026 14:26
- News subject
- Earnings
- Why this score
- Operating growth
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 12.1% · 0.2d old
- Duplicates
- 127 consolidated
#645Tone
finance.yahoo.comDirect company coverageStored article
Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 from $50. Analyst Kerry Holford argues that the Wegovy pill upside her Buy rating was built on has already played out. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Berenberg and broader consensus now model around DKK 15 billion of Wegovy pill sales
DOWNGRADEDowngradeEARNINGSEarningsPHARMAPharma
- Published
- 12 Aug 2026 17:29
- News subject
- Analyst action
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 4.6% · 1.1d old
- Duplicates
- 383 consolidated
#775Tone
finance.yahoo.comDirect company coverageStored article
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?
Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity franchise. Notably, sales of injectable Wegovy for obesity were flat year over year in the second quarter, reflecting intensifying competition from rival Eli Lilly's LLY Zepbound injection and raising concerns about Novo Nordisk's ability to sustain momentum in the highly competitive GLP-1 market. Novo
DIABETESDiabetesEARNINGSEarningsFOURTH QUARTERFourth Quarter
- Published
- 12 Aug 2026 15:10
- News subject
- Earnings
- Why this score
- Beat expectations
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 13.4% · 1.2d old
- Duplicates
- 383 consolidated
#850Tone
finance.yahoo.comDirect company coverageStored article
Cloud AI Today - Novo Nordisk Partners With AWS For AI-Driven Drug Discovery
Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development teams to streamline the process of bringing new medicines to market. As part of this agreement, AWS becomes Novo Nordisk's preferred cloud provider and strategic AI partner, leveraging AWS's AI technologies to compress timelines from drug target identification to clinica
AICLOUDCloudEARNINGSEarnings
- Published
- 11 Aug 2026 12:38
- News subject
- Earnings
- Why this score
- No clear positive or negative phrase
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 3.4% · 2.3d old
- Duplicates
- 767 consolidated
#943Tone
nasdaq.comDirect company coverageStored article
NVO Crosses Above Average Analyst Target
In recent trading, shares of Novo-Nordisk AS (Symbol: NVO) have crossed above the average analyst 12-month target price of $47.48, changing hands for $47.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 10 different analyst
ETFSEtfsMARKETSMarketsPRICE TARGETPRICE-TARGET
- Published
- 11 Aug 2026 11:43
- News subject
- Analyst action
- Why this score
- Negative financial language
- Company focus
- Company discussed · 86%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 4.2% · 2.4d old
- Duplicates
- 384 consolidated
#1050Tone
finance.yahoo.comDirect company coverageStored article
Novo Nordisk (CPSE:NOVO B) Wins Dutch Injunction Over Compounded Semaglutide Spray
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk (CPSE:NOVO B) secured a Dutch court injunction against Ceban Ziekenhuisfarmacie over an unapproved compounded semaglutide nasal spray. The ruling blocks production and distribution of the compounded nasal spray in the Netherlands for infringing Novo Nordisk's semaglutide patent. The decision reinforces Novo Nordisk's intellectual property position around Wegovy, Ozempic and Rybelsus and limits non approved competitor versions. Patent enforcement around key obesity and
BALANCE SHEETBalance SheetHEALTHCAREHealthcarePATENT-ENFORCEMENTPHARMA
- Published
- 08 Aug 2026 23:10
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.6% · 4.9d old
- Duplicates
- 767 consolidated
#1150Tone
finance.yahoo.comDirect company coverageStored article
Novo Nordisk A/S Q2 Earnings Call Highlights
Key Points Interested in Novo Nordisk A/S? Here are five stocks we like better. Novo Nordisk raised its 2026 outlook after a better-than-expected start to the year, reporting Q2 adjusted sales of DKK 78.5 billion and 7% growth at constant exchange rates. However, lower realized prices, manufacturing costs and currency effects reduced the adjusted gross margin to 78.2% from 82.7%. Oral Wegovy drove obesity-treatment momentum. The U.S. pill surpassed 5 million prescriptions and captured about 90% of the oral obesity-drug market, while roughly 80% of users were new to GLP-1 treatments; internatio
CARDIOVASCULARCardiovascularDIABETESDiabetesEARNINGSEarnings
- Published
- 08 Aug 2026 22:03
- News subject
- Earnings
- Why this score
- Guidance raised, Deteriorating financial comparison
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 3.4% · 4.9d old
- Duplicates
- 767 consolidated
#1225Tone
finance.yahoo.comDirect company coverageStored article
Novo Nordisk Stock Rises After GLP-1 Antitrust Win
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant behind Ozempic and Wegovy, edged nearly 2% higher during Friday's U.S. regular session after a federal judge threw out an antitrust lawsuit against Novo and Eli Lilly (NYSE:LLY). According to Reuters, the case was filed by Strive Specialties, which claimed the drugmakers unfairly limited access to compounded GLP-1 weight-loss drugs through exclusive telehealth partnerships. Warning! GuruFocus has detected 4 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator
ANTITRUSTAntitrustLAWSUITLawsuitOBESITY-DRUGSObesity Drugs
- Published
- 07 Aug 2026 19:52
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 8.1% · 6.0d old
- Duplicates
- 767 consolidated
#1350Tone
The Wall Street JournalDirect company coverageScored from headlineSource lookup
How Novo Nordisk’s CEO Says He Is Shifting the Company’s Perspective
- Published
- 06 Aug 2026 12:52
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.6% · 7.3d old
- Duplicates
- 9 consolidated
#1450Tone
simplywall.stDirect company coverageScored from headlineSource lookup
Novo Nordisk (NYSE:NVO) Stock May Be Below Fair Value On ZEUS Trial Fallout
- Published
- 06 Aug 2026 06:08
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.3% · 7.6d old
- Duplicates
- 9 consolidated
#1550Tone
foreignpolicyjournal.comDirect company coverageScored from headlineSource lookup
Novo Nordisk (NYSE: NVO) Shares Tumble After Experimental Heart Drug Fails Key Late-Stage Trial
- Published
- 04 Aug 2026 00:58
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.1% · 9.8d old
- Duplicates
- 9 consolidated
#1650Tone
Market sourceDirect company coverageScored from headlineSource lookup
Novo Nordisk (NVO) Trial Setback Hits Sentiment, Is The Stock Still Cheap?
- Published
- 02 Aug 2026 16:04
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 11.2d old
- Duplicates
- 9 consolidated
#1759Tone
foreignpolicyjournal.comDirect company coverageScored from headlineSource lookup
Novo Nordisk (NYSE: NVO) Stock Price Trades At Sharp Discount To Fair Value Despite Trial And Legal Headwinds
- Published
- 02 Aug 2026 03:23
- News subject
- Market update
- Why this score
- Positive valuation view
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.1% · 11.7d old
- Duplicates
- 9 consolidated
#1846Tone
MT NewswiresDirect company coverageScored from headlineSource lookup
Novo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events in Phase 3 Trial; Shares Fall Pre-Bell
- Published
- 31 Jul 2026 12:16
- News subject
- Market update
- Why this score
- Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 13.3d old
- Duplicates
- 9 consolidated
#1950Tone
Seeking AlphaDirect company coverageScored from headlineSource lookup
Novo Nordisk Stock: Too Late For A Great Opportunity (NYSE:NVO)
- Published
- 31 Jul 2026 11:12
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 13.4d old
- Duplicates
- 9 consolidated
#2035Tone
Seeking AlphaDirect company coverageScored from headlineSource lookup
Novo Nordisk to face shareholder lawsuit accusing fraud over CagriSema trial (NVO:NYSE)
- Published
- 28 Jul 2026 20:31
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 3.7% · 16.0d old
- Duplicates
- 9 consolidated
#2165Tone
foreignpolicyjournal.comDirect company coverageScored from headlineSource lookup
Novo Nordisk (NYSE: NVO) Advances DKK 15 Billion Share Buyback With Fresh Weekly Transactions
- Published
- 28 Jul 2026 12:23
- News subject
- Capital return
- Why this score
- Share Buyback
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 1.3% · 16.3d old
- Duplicates
- 9 consolidated
#2250Tone
MT NewswiresDirect company coverageScored from headlineSource lookup
Market Chatter: Novo Nordisk Seeks Immediate Court Order Against Lilly's Weight-Loss Drug Ads
- Published
- 24 Jul 2026 11:02
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 20.4d old
- Duplicates
- 9 consolidated
#2350Tone
simplywall.stDirect company coverageScored from headlineSource lookup
Novo Nordisk (NVO) Faces A Fair Value Debate, Is The Stock A Bargain?
- Published
- 24 Jul 2026 04:11
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 20.7d old
- Duplicates
- 9 consolidated
#2450Tone
Market sourceDirect company coverageScored from headlineSource lookup
Here's Why Novo Nordisk (NVO) Fell More Than Broader Market
- Published
- 23 Jul 2026 09:35
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 21.4d old
- Duplicates
- 9 consolidated
#2557Tone
Ad-hoc-news.deDirect company coverageScored from headlineSource lookup
Novo Nordisk stock trades near record territory as Ozempic and Wegovy drive growth
- Published
- 22 Jul 2026 06:27
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 22.6d old
- Duplicates
- 9 consolidated
#2650Tone
Stock TitanDirect company coverageScored from headlineSource lookup
Novo Nordisk (NYSE: NVO) reports 24,959,179 shares repurchased in 2026 programme
- Published
- 21 Jul 2026 11:00
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 23.4d old
- Duplicates
- 9 consolidated
#2757Tone
ad-hoc-news.deDirect company coverageScored from headlineSource lookup
Novo Nordisk stock trades near record levels as Wegovy momentum supports earnings outlook
- Published
- 19 Jul 2026 22:15
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.3% · 24.9d old
- Duplicates
- 18 consolidated
#2843Tone
Motley FoolDirect company coverageScored from headlineSource lookup
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1
- Published
- 18 Jul 2026 21:30
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 25.9d old
- Duplicates
- 9 consolidated
#2950Tone
Seeking AlphaDirect company coverageScored from headlineSource lookup
Novo Nordisk: The Oral Wegovy Promise (NYSE:NVO)
- Published
- 17 Jul 2026 17:29
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 27.1d old
- Duplicates
- 18 consolidated
#3050Tone
WSJDirect company coverageScored from headlineSource lookup
In the Weight-Loss Wars, Novo’s Obesity Pill Is Pulling Way Ahead of Lilly’s
- Published
- 15 Jul 2026 11:11
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 29.4d old
- Duplicates
- 9 consolidated
Earlier company news
NVO news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 27 older NVO headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to NVO, but the headline and available text are not mainly about Novo Nordisk A/S. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of NVO sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.